Life Sciences & Biotechnology
Title : | Repurposing of recently FDA approved drugs alone and in combination with standard antibiotics against bacterial infections using Network Pharmacology and In-vitro techniques |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Anoop kumar, Delhi Pharmaceutical Sciences And Research University, New Delhi |
Timeline Start Year : | 2022 |
Timeline End Year : | 2024 |
Contact info : | inspireanoop87@gmail.com |
Equipments : | CPU Processing with GPU acceleration |
Details
Executive Summary : | Bacterial infections are a growing threat to human health and population, with antibiotic resistance causing a dramatic increase in infections. Despite the availability of antibiotics like beta-lactams, protein synthesis inhibitors, DNA gyrase inhibitors, and aminoglycosides, these drugs are associated with adverse drug reactions (ADRs) such as nephrotoxicity, hepatotoxicity, renal failure, thrombocytopenia, neutropenia, and angioedema. Therefore, there is a need to develop new chemical entities against bacterial infections. Drug repurposing begins with known pharmaceutical agents with a history of clinical use, providing a wealth of data for clinicians and researchers. The FDA has approved over 200 drugs in the last five years for various diseases, but the other uses of these drugs beyond their approved therapeutic indications are unclear. The proposed proposal aims to screen recently FDA-approved drugs against various bacteria targets using molecular docking and molecular dynamics studies. The antibacterial mechanism of selected molecules will be predicted using network pharmacology approaches, and target-based assays under in vitro conditions will be conducted with selected molecules alone and in combination with standard antibiotics. These promising molecules can be further explored against specific resistant bacterial strains based on the results of the proposed study. |
Total Budget (INR): | 26,05,800 |
Organizations involved